SEC Comment Letter for VACCINEX, INC. (VCNX) (CIK 0001205922) (VCNX) — Feb 19, 2020
VACCINEX, INC. (VCNX) (CIK 0001205922)
Date: Feb. 19, 2020 · CIK: 0001205922 · Accession: 0000000000-20-001533
AI Filing Summary & Sentiment
File numbers found in text: 333-236417
Letter
February 19, 2020 Maurice Zauderer, Ph.D. President and Chief Executive Officer Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, NY 14620 Re:Vaccinex, Inc. Registration Statement on Form S-3 Filed February 13, 2020 File No. 333-236417 Dear Dr. Zauderer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at 202-551-5019 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: William Intner, Esq.
Show Raw Text
February 19, 2020
Maurice Zauderer, Ph.D.
President and Chief Executive Officer
Vaccinex, Inc.
1895 Mount Hope Avenue
Rochester, NY 14620
Re:Vaccinex, Inc.
Registration Statement on Form S-3
Filed February 13, 2020
File No. 333-236417
Dear Dr. Zauderer:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at 202-551-5019 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: William Intner, Esq.